Medtronic PLC $MDT Stock Bought by State Street Corp

Medtronic logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • State Street increased its Medtronic position by 4.1% in the third quarter, adding about 2.59 million shares to hold 65.99 million shares worth roughly $5.74 billion.
  • Medtronic beat quarterly earnings and revenue estimates, reporting EPS of $1.45 and revenue of $9.76 billion; revenue rose 13.7% year over year.
  • Analysts’ consensus rating is Moderate Buy, with an average price target of $104.17. Medtronic’s CEO and an EVP also sold shares under pre-arranged trading plans.
  • MarketBeat previews the top five stocks to own by December 1st.

State Street Corp lifted its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 4.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 65,987,354 shares of the medical technology company's stock after purchasing an additional 2,588,039 shares during the quarter. State Street Corp owned 5.16% of Medtronic worth $5,741,306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. raised its stake in Medtronic by 0.7% during the 2nd quarter. BlackRock Inc. now owns 114,020,787 shares of the medical technology company's stock worth $8,919,846,000 after buying an additional 838,220 shares during the period. Bank of America Corp DE grew its stake in Medtronic by 5.4% in the first quarter. Bank of America Corp DE now owns 26,015,003 shares of the medical technology company's stock valued at $2,254,200,000 after acquiring an additional 1,343,220 shares during the period. First Eagle Investment Management LLC grew its stake in Medtronic by 1.2% in the third quarter. First Eagle Investment Management LLC now owns 13,948,408 shares of the medical technology company's stock valued at $1,203,608,000 after acquiring an additional 164,425 shares during the period. Amundi grew its stake in Medtronic by 36.3% in the first quarter. Amundi now owns 6,070,236 shares of the medical technology company's stock valued at $525,986,000 after acquiring an additional 1,616,739 shares during the period. Finally, The Manufacturers Life Insurance Company increased its holdings in shares of Medtronic by 1.2% in the first quarter. The Manufacturers Life Insurance Company now owns 5,413,353 shares of the medical technology company's stock worth $469,065,000 after acquiring an additional 63,296 shares in the last quarter. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Price Performance

Shares of NYSE MDT opened at $99.88 on Friday. The firm has a market cap of $127.75 billion, a PE ratio of 24.60, a PEG ratio of 2.41 and a beta of 0.56. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33. The company has a fifty day moving average price of $94.62 and a 200 day moving average price of $88.45.

Medtronic (NYSE:MDT - Get Free Report) last released its earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.06. The firm had revenue of $9.76 billion during the quarter, compared to analysts' expectations of $9.55 billion. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The company's revenue was up 13.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts predict that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medtronic news, CEO Geoffrey Martha sold 50,000 shares of the business's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $95.00, for a total value of $4,750,000.00. Following the sale, the chief executive officer owned 277,866 shares in the company, valued at approximately $26,397,270. The trade was a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the company's stock in a transaction that occurred on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the transaction, the executive vice president directly owned 105,916 shares of the company's stock, valued at approximately $10,167,936. This trade represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on MDT. TD Cowen set a $110.00 price target on Medtronic and gave the stock a "buy" rating in a research report on Tuesday. Wells Fargo & Company lifted their price objective on Medtronic from $102.00 to $104.00 and gave the company an "overweight" rating in a report on Wednesday, September 2nd. Bank of America boosted their price objective on Medtronic from $95.00 to $110.00 and gave the company a "buy" rating in a research report on Wednesday, September 2nd. Mizuho set a $115.00 target price on Medtronic in a research note on Wednesday, September 2nd. Finally, Wall Street Zen cut Medtronic from a "buy" rating to a "hold" rating in a research note on Monday, November 16th. Eighteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $104.17.

Check Out Our Latest Report on Medtronic

About Medtronic

(Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

See Also

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

Institutional Ownership by Quarter for Medtronic (NYSE:MDT)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Medtronic Right Now?

Before you consider Medtronic, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medtronic wasn't on the list.

While Medtronic currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines